B of A Securities Initiates Coverage On Definium Therapeutics with Buy Rating, Announces Price Target of $75

Benzinga Newsdesk www.benzinga.com Positive 54.3%

Neg 0% Neu 0% Pos 54.3%

B of A Securities analyst Tazeen Ahmad initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Buy rating and announces Price Target of $75.